How does overexpression of endothelial growth factor receptor (EGFR) affect the prognosis of non–small cell lung cancer (NSCLC)?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

Overexpression of EGFR is common in NSCLC. Cancers overexpressing EGFR have been shown to have increased resistance to therapy, increased metastatic potential, and thus a poorer prognosis.

Stimulation of the EGFR pathway leads to increased autophosphorylation of a tyrosine kinase pathway associated with EGFR. This leads to a series of intracellular events culminating in increased mitotic and growth potential, increased ability to metastasize, and increased angiogenesis (new blood vessel formation) in the cancer cells.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!